Skip to content
Clinical Trials – home
Not yet recruiting

High‑dose versus standard oral terbinafine for treating tinea capitis in children

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

What is this trial about?

A plain-language summary of the goals, design and what participants do

Tinea capitis is a common fungal infection of the scalp that causes itchy, scaly patches and sometimes hair loss in children. The study examines two oral doses of the antifungal medicine terbinafine: a higher dose of 500 mg taken once daily and a standard dose of 250 mg taken once daily. Both doses are given by mouth and are intended to clear the infection from the scalp and hair.

The purpose of the study is to compare how well the high dose works compared with the standard dose in achieving a clinical cure, meaning the scalp looks clear or almost clear, together with a negative mycological culture, a laboratory test that shows no fungus present, after four weeks of treatment. Children will receive the assigned medication for several weeks and will be examined by a doctor at weeks 2, 4, and 8. During these visits the doctor will look at how the scalp looks, check the laboratory test results, and score any remaining signs using the Total Signs and Symptoms Score, a simple number that reflects how many symptoms are still present. Hair regrowth in areas that had lost hair will also be noted. The study follows participants for a short period to see if the improvement is maintained.

The research process

The trial runs in 7 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Enrollment and Randomization

    After giving informed consent, you are entered into the study and assigned to one of two groups.

    One group receives a high dose of terbinafine (500 mg taken orally each day). The other group receives a standard dose of terbinafine (250 mg taken orally each day).

  2. Step 2

    Baseline Assessment

    A clinician examines your scalp and records the severity of the infection.

    A small sample from the scalp is collected for laboratory testing (mycological culture) to identify the fungus.

    All findings are documented before you start the medication.

  3. Step 3

    Start of Medication

    You begin taking the assigned oral dose of terbinafine each day.

    The medication is taken by mouth with water.

    You continue the medication for the duration of the study, which includes visits up to week 8.

  4. Step 4

    Visit at Week 2

    You return to the clinic two weeks after starting the medication.

    The clinician checks your scalp for improvement and records any side effects you may have experienced.

    Another scalp sample is taken for culture to see if the fungus is still present.

    The results help determine early treatment success.

  5. Step 5

    Visit at Week 4

    Four weeks after starting the medication, you attend a follow‑up visit.

    The clinician assesses whether the infection is clear or almost clear and looks for signs of hair regrowth.

    A third scalp culture is performed to confirm that the fungus is no longer detectable.

    These findings are used to evaluate the primary outcome of the study.

  6. Step 6

    Visit at Week 8

    Eight weeks after the start of treatment, you have a final clinic visit.

    The clinician examines the scalp to see if the cure has been maintained and whether new hair has grown back.

    Any remaining safety concerns are reviewed.

  7. Step 7

    Study Completion

    After the week 8 visit, the study participation ends.

    All data collected during the visits are compiled for analysis.

    You receive a summary of your individual results and any final safety information.

Who can join the trial?

6 criteria

  • Be older than 2 years but younger than 18 years.
  • Weigh at least 10 kg (about 22 lb).
  • Have a doctor‑confirmed diagnosis of Tinea capitis (a fungal infection of the scalp) based on a clinical examination (a physical check‑up).
  • Be able to follow the study rules and take the medication as instructed.
  • Be covered by or eligible for social security (government health coverage).
  • Have a parent or legal guardian sign a written informed consent form agreeing to take part.

Who cannot join the trial?

11 criteria

  • Already took part in this study before for Tinea capitis.
  • Has a lab test called a mycological culture (a test that looks for fungus) already done before joining.
  • Has a sibling coming in on the same day for Tinea capitis, which could cause mix‑ups in treatment groups.
  • The diagnosis of Tinea capitis is not clear or is uncertain.
  • Cannot take the medicine terbinafine because of any of the following: renal failure (serious kidney problem with eGFR < 30, a measure of kidney function), known long‑term or active liver disease, or an allergy (hypersensitivity).
  • Cannot use the antifungal cream or lotion because of an allergy (hypersensitivity).
  • Is pregnant or breastfeeding.
  • Is a young woman who could become pregnant and is not using a reliable birth‑control method.
  • Has taken an oral (systemic) antifungal medicine in the past three months.
  • Has used an antifungal cream, lotion, or other topical treatment in the past two weeks.
  • Is currently taking the medicines deutetrabenazine or tetrabenazine.
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Terbinafine

    is an oral medication given at a higher amount in this study. It is being tested to see if taking more of the medicine helps children with scalp ringworm (tinea capitis) heal faster and completely, with no fungus left in lab tests after four weeks.

  • Terbinafine

    is also given at the usual amount that doctors normally prescribe. This standard dose serves as the comparison group, helping researchers understand whether the higher amount provides any extra benefit over the regular treatment.

What is already known about the treatment

  • Terbinafine (500 mg oral)

    This medication is taken by mouth as a daily tablet of 500 mg; it is an approved antifungal used to treat fungal infections of the scalp, especially tinea capitis in children. It works by blocking an enzyme that the fungus needs to build its cell wall, which stops the fungus from growing and eventually kills it. Terbinafine belongs to the allylamine class of antifungal drugs and is well described in medical literature. It is commonly prescribed for skin and nail fungal infections.

  • Terbinafine (250 mg oral)

    This medication is taken by mouth as a daily tablet of 250 mg; it is the standard dose of an approved antifungal used for treating scalp ringworm in children. It acts by inhibiting the fungal enzyme that makes the cell wall, preventing the fungus from multiplying. Terbinafine is classified as an allylamine antifungal and has a long history of use in medical practice. It is widely used for various skin and nail fungal infections.

Investigated diseases

Tinea capitis - Tinea capitis is a fungal infection of the scalp caused by dermatophyte organisms that invade the hair shafts. It begins with small, scaly patches that may be mildly itchy and can expand as the fungus spreads. As the infection progresses, hairs within the affected area become broken or fall out, creating round, bald spots. In some cases the lesions become inflamed and develop a raised, pus‑filled surface, and the infection can be transmitted to other people through close contact.
Trial detailsLast updated 19 Nov 2026
Age0-17PhasePhase IIITrial ID2026-525807-28-00Protocol codeDR250358Estimated enrolment210 patientsSponsorCentre Hospitalier Regional Universitaire De Tours

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.